Search

Displaying results 431 - 440 of 10000 in total
  1. Drug

    Viltolarsen

    go.drugbank.com/drugs/DB15005
    ApprovedInvestigational

    Duchenne muscular dystrophy (DMD) is an X-linked recessive allelic disorder characterized by a lack of functional dystrophin protein, which leads to progressive ambulatory, pulmonary, and cardiac function … links between nucleotides are replaced with a phosphorodiamidate linkage.

  2. Drug

    Actelion-1

    go.drugbank.com/drugs/DB05367
    Experimental

    Actelion-1 is a tissue-targeting Endothelin Receptor Antagonist that has been discovered by Actelion Pharmaceuticals.

    Categories: Endothelin A Receptor Antagonists, Heterocyclic Compounds, 1-RingSynonyms: Actelion-1
  3. Drug

    Sodium phosphate, dibasic, unspecified form

    go.drugbank.com/drugs/DB14504
    Approved

    Mixtures: Fresh Prep Laxative, gent-L-tip
  4. Drug

    Pegvaliase

    go.drugbank.com/drugs/DB12839
    ApprovedInvestigational

    The primary goal of lifelong treatment of PKU, as recommended by the American College of Medical Genetics and Genomics (ACMG) guidelines, is to maintain blood Phe concentration in the range of 120 µmol … /L to 3690 µmol/L [A33286].

  5. Drug

    Bromotheophylline

    go.drugbank.com/drugs/DB14018
    Approved

    Bromotheophylline is the active moiety of pamabrom, a mixture of 2-amino-2-methyl-propanol and bromotheophylline. … [A33018] Bromotheophylline is categorized on the FDA as a drug substance with an inactive state since March, 1980.

    Mixtures: Pre Menstrual relief maximum strengthCategories: Cytochrome P-450 Substrates, Heterocyclic Compounds, 2-Ring
  6. Drug

    Protamine sulfate

    go.drugbank.com/drugs/DB09141
    ApprovedInvestigational

    Despite the relative importance of protamine sulfate's medical indication, the medication can notoriously cause a variety of potentially rare but genuinely severe adverse effects that include systemic … recovery of a patient after the procedure [A174778, A174781, L5371].

    Products: PROLFAT 50 MG/5 ML IV ENJEKSİYONLUK ÇÖZELTİ, 1 ADET, PAMINTU 10 MG/ML ENJEKSIYONLUK ÇÖZELTI IÇEREN FLAKON,5 ML 1 ADET
  7. Target

    Serine/arginine-rich splicing factor 4

    go.drugbank.com/bio_entities/BE0009120
    TargetHumans

    Plays a role in alternative splice site selection during pre-mRNA splicing. Represses the splicing of MAPT/Tau exon 10

    Synonyms: Pre-mRNA-splicing factor SRP75
  8. Drug

    Rituximab

    go.drugbank.com/drugs/DB00073
    ApprovedInvestigational

    FDA in 1997 as a single agent to treat patients with B-cell Non-Hodgkin's Lymphoma (NHL) [L4811], however, has now been approved for a variety of conditions [FDA label]. … Rituximab is a genetically engineered chimeric murine/human monoclonal antibody directed against the CD20 antigen found on the surface of normal and malignant B lymphocytes.

    Categories: CHOP-R chemotherapy regimenProducts: TRUXIMA®, BIORIMAB®
  9. Drug

    Onasemnogene abeparvovec

    go.drugbank.com/drugs/DB15528
    ApprovedInvestigational

    muscular atrophy (SMA) and a specific mutation in the survival motor neuron 1 (SMN1) gene. … Developed by AveXis, a Novartis company,[A187253] onasemnogene abeparvovec is commonly marketed as Zolgensma®, which is available as a single-dose intravenous infusion.

  10. Drug

    Tianeptine

    go.drugbank.com/drugs/DB09289
    Investigational

    Tianeptine was discovered and patented by The French Society of Medical Research in the 1960s [L2946]. … Tianeptine is a drug used primarily in the treatment of major depressive disorder and has been studied in the treatment of irritable bowel syndrome (IBS) [A31983].

    Categories: Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 Substrates